Gossamer Bio, Inc. (GOSS)

Market Cap	779.43M
Revenue (ttm)	n/a
Net Income (ttm)	-229.90M
Shares Out	91.18M
EPS (ttm)	-3.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,475,860
Open	8.23
Previous Close	8.25
Day's Range	8.12 - 9.05
52-Week Range	5.64 - 15.2
Beta	0.88
Analysts	Buy
Price Target	18.20 (+101.8%)
Earnings Date	Nov 14, 2022

About GOSS

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disea...

• Industry: Biotechnology
• IPO Date: Feb 8, 2019
• CEO: Sheila Gujrathi
• Employees: 185
• Stock Exchange: NASDAQ
• Ticker Symbol: GOSS

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 19 analysts, the average rating for GOSS stock is "Buy." The 12-month stock price forecast is 18.2, which is an increase of 101.77% from the latest price.

Price Target

$18.2

(101.77% upside)

Analyst Consensus: Buy

Stock Forecasts